Pricing

Krystal Biotech Inc (KRYS)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO: Krish S. Krishnan
Employees: 210
Web site: krystalbio.com
2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
(412) 586-5830
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available